0000899243-21-038068.txt : 20210928 0000899243-21-038068.hdr.sgml : 20210928 20210928161016 ACCESSION NUMBER: 0000899243-21-038068 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210924 FILED AS OF DATE: 20210928 DATE AS OF CHANGE: 20210928 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: DEKKERS MARIJN E CENTRAL INDEX KEY: 0001216068 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39311 FILM NUMBER: 211286912 MAIL ADDRESS: STREET 1: GENERAL ELECTRIC COMPANY STREET 2: 41 FARNSWORTH STREET CITY: BOSTON STATE: MA ZIP: 02210 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Cerevel Therapeutics Holdings, Inc. CENTRAL INDEX KEY: 0001805387 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 222 JACOBS STREET STREET 2: SUITE 200 CITY: CAMBRIDGE STATE: MA ZIP: 02141 BUSINESS PHONE: 844-304-2048 MAIL ADDRESS: STREET 1: 222 JACOBS STREET STREET 2: SUITE 200 CITY: CAMBRIDGE STATE: MA ZIP: 02141 FORMER COMPANY: FORMER CONFORMED NAME: ARYA Sciences Acquisition Corp II DATE OF NAME CHANGE: 20200303 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-09-24 0 0001805387 Cerevel Therapeutics Holdings, Inc. CERE 0001216068 DEKKERS MARIJN E C/O CEREVEL THERAPEUTICS HOLDINGS, INC. 222 JACOBS STREET, SUITE 200 CAMBRIDGE MA 02141 1 0 0 0 Common Stock 2021-09-24 4 M 0 14270 A 42810 D Common Stock 633350 I See footnote Restricted Stock Units 2021-09-24 4 M 0 14270 0.00 D Common Stock 14270 0 D The shares reported in this transaction represent Restricted Stock Units ("RSUs") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. Shares held by Novalis LifeSciences Investments I, L.P., or Novalis LifeSciences. Marijn Dekkers, the Manager of the general partner of Novalis LifeSciences, has sole voting and dispositive power over the shares held by Novalis LifeSciences and, as a result, may be deemed to share beneficial ownership of the shares held by Novalis LifeSciences. 14,270 RSUs vested on September 24, 2021, the third anniversary of the vesting commencement date of September 24, 2018. /s/ Mark Bodenrader, as Attorney-in-Fact 2021-09-28